Head-to-head evidence
HNC364 vs Rasagiline (Azilect)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: MAO-B · full Parkinson's Disease pipeline
HNC364
Developed by Guangzhou Henovcom Bioscience Co. Ltd.
NCT05523570 · Phase 1 · completed
Participants were not randomized and neither they nor the investigators were blinded, and there was no placebo or comparator group, so this design cannot separate a real drug effect from chance, natural variation, or expectation. Results have not yet been posted.
Next expected readout: December 2026 · NCT06798519 (registry estimate)
Rasagiline (Azilect)
Marketed by Teva Pharmaceutical Industries
NCT01479530 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled trial with 321 participants, with 158 assigned to placebo and 163 to rasagiline. The primary clinical endpoint—change in daily OFF time—favored rasagiline and was statistically significant (p=0.0228).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HNC364's landscape · Rasagiline (Azilect)'s landscape